Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Michel Dahan


  • Svp, Chief Business Officer at Akebia Therapeutics Inc. (AKBA), 2019-04-12
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
AKBA $19.64 1,398 95,826 2017-10-02 Filing
AKBA $19.30 5,000 97,224 2017-09-28 Filing
AKBA $15.00 5,000 102,224 2017-08-15 Filing
AKBA $14.26 1,399 107,224 2017-07-03 Filing
AKBA $9.18 1,401 108,623 2017-04-03 Filing